Skip to main
CAH

Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health (CAH) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Cardinal Health is a strong player in the US pharmaceutical market, with a diversified portfolio and a strong presence in the healthcare supply chain. Their strategic investments and partnerships are expected to drive growth and margin expansion in the future. While there are risks in the industry such as changes in drug pricing and legal issues, the company's focus on long-term solutions and growth opportunities make it a favorable investment. Financially, Cardinal Health is projected to continue increasing revenue and earnings per share in the coming years through operational execution and strategic investments, showcasing their strong fundamentals and potential for long-term success.

Bears say

Cardinal Health is heavily reliant on a few large customers, which creates a risk of revenue loss or margin pressure. Their business segment that relies on international markets also introduces complexities and risks due to exposure to geopolitical and macroeconomic disruptions. We are also concerned about the potential impact of ongoing legal proceedings related to the distribution of controlled substances and the uncertainty around the durability and margin impact of the rapid growth of GLP-1 drugs on their business.

Cardinal Health (CAH) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardinal Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardinal Health (CAH) Forecast

Analysts have given Cardinal Health (CAH) a Buy based on their latest research and market trends.

According to 12 analysts, Cardinal Health (CAH) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $226.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $226.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardinal Health (CAH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.